Michael Burkes  Brophy net worth and biography

Michael Brophy Biography and Net Worth

CFO of Natera
Mike Brophy has served as our Chief Financial Officer since February 2017. Previously, he served as our Senior Vice President, Finance and Investor Relations since September 2016, and prior to that, as our Vice President, Corporate Development and Investor Relations since September 2015. Prior to joining Natera, Mr. Brophy served as an executive director from January 2014 to September 2015, and as a vice president prior to that, in the investment banking division at Morgan Stanley where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds an M.B.A. from the University of California, Los Angeles and a Bachelor of Science in Economics from the United States Air Force Academy.

What is Michael Burkes Brophy's net worth?

The estimated net worth of Michael Burkes Brophy is at least $19.04 million as of January 27th, 2025. Mr. Brophy owns 108,032 shares of Natera stock worth more than $19,042,801 as of January 30th. This net worth approximation does not reflect any other investments that Mr. Brophy may own. Additionally, Mr. Brophy receives a salary of $611,350.00 as CFO at Natera. Learn More about Michael Burkes Brophy's net worth.

How old is Michael Burkes Brophy?

Mr. Brophy is currently 44 years old. There are 4 older executives and no younger executives at Natera. The oldest executive at Natera is Mr. Daniel Rabinowitz L.L.M., Secretary & Chief Legal Officer, who is 55 years old. Learn More on Michael Burkes Brophy's age.

What is Michael Burkes Brophy's salary?

As the CFO of Natera, Inc., Mr. Brophy earns $611,350.00 per year. The highest earning executive at Natera is Mr. Steven Leonard Chapman, CEO & Director, who commands a salary of $1,150,000.00 per year. Learn More on Michael Burkes Brophy's salary.

How do I contact Michael Burkes Brophy?

The corporate mailing address for Mr. Brophy and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at mbrophy@natera.com. Learn More on Michael Burkes Brophy's contact information.

Has Michael Burkes Brophy been buying or selling shares of Natera?

Over the course of the past ninety days, Michael Burkes Brophy has sold $4,673,946.69 of Natera stock. Most recently, Michael Burkes Brophy sold 1,442 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $161.87, for a transaction totalling $233,416.54. Following the completion of the sale, the chief financial officer now directly owns 108,032 shares of the company's stock, valued at $17,487,139.84. Learn More on Michael Burkes Brophy's trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), John Fesko (Insider), James Healy (Director), Gail Marcus (Director), Solomon Moshkevich (President, Clinical Diagnostics), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, insiders at the medical research company sold shares 76 times. They sold a total of 854,733 shares worth more than $95,355,379.91. The most recent insider tranaction occured on January, 27th when CFO Michael Burkes Brophy sold 1,442 shares worth more than $233,416.54. Insiders at Natera own 7.6% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 1/27/2025.

Michael Burkes Brophy Insider Trading History at Natera

Michael Burkes Brophy Buying and Selling Activity at Natera

This chart shows Michael Burkes Brophy's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$4.67MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Natera Company Overview

Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $176.27
Low: $169.04
High: $177.90

50 Day Range

MA: $166.56
Low: $155.20
High: $176.61

2 Week Range

Now: $176.27
Low: $64.74
High: $183.00

Volume

1,598,769 shs

Average Volume

1,419,899 shs

Market Capitalization

$23.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65